Stage III Colon Cancer Clinical Trial
Official title:
A Pilot Study to Determine the Feasibility of a Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer
This pilot clinical trial studies the feasibility of a low glycemic load diet in patients with stage I-III colon cancer. A low glycemic load diet includes foods that have low scores on the glycemic index. The glycemic index is a scale that measures how much a certain carbohydrate causes a person's blood sugar to rise. A low glycemic load diet may help decrease the chance of cancer coming back and improve the survival in patients with colon cancer.
PRIMARY OBJECTIVES:
I. To determine the feasibility of following a low or medium glycemic load diet in patients
with stage I-III (local-regional) colon cancer.
SECONDARY OBJECTIVES:
I. To determine patient-reported acceptability of diet. II. To determine nutritionist
resources utilized. III. To evaluate the effect of lowering dietary glycemic load on body
mass index (BMI), lipid metabolism and pro-oncogenic intermediaries of cellular metabolism.
OUTLINE: Patients are sequentially enrolled in 1 of 4 possible cohorts as needed based on the
feasibility of the prior cohort.
COHORT 1: Patients follow a low glycemic load diet with standard dietary intervention
(contact with nutritionist in person every 2 weeks with phone contact on the alternating
weeks) for 12 weeks.
COHORT 2: Patients follow a low glycemic load diet with intensified dietary intervention
(contact with nutritionist in person every week) for 12 weeks.
COHORT 3: Patients follow a medium glycemic load diet with standard dietary intervention for
12 weeks.
COHORT 4: Patients follow a medium glycemic load diet with intensified dietary intervention
for 12 weeks.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00025337 -
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
|
Phase 3 | |
Active, not recruiting |
NCT04164069 -
Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
|
Phase 1 | |
Not yet recruiting |
NCT05870800 -
Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer
|
Phase 2 | |
Recruiting |
NCT02280278 -
Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy
|
Phase 3 | |
Completed |
NCT01191684 -
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
|
Phase 1 | |
Completed |
NCT00551421 -
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03958435 -
Real-world Retrospective Data Analysis of Adjuvant Therapy for Patients With Stage II-III Colon Cancer After Radical Surgery
|
||
Completed |
NCT01890213 -
Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer
|
Phase 1 | |
Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03255434 -
LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy
|
Phase 2 | |
Completed |
NCT01126346 -
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
|
N/A | |
Terminated |
NCT00087191 -
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
|
N/A | |
Completed |
NCT00003835 -
Combination Chemotherapy in Treating Patients With Stage III Colon Cancer
|
Phase 3 | |
Recruiting |
NCT05062889 -
Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
|
Phase 2 | |
Recruiting |
NCT04416490 -
Oxaliplatin Adjuvant Chemotherapy After Curative Resection of Primary Colon Cancer
|
||
Active, not recruiting |
NCT02836977 -
Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen in Patients With Stage III Colon Cancer After Radical Resection
|
N/A | |
Completed |
NCT00005818 -
SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00019006 -
Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05174169 -
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT06287814 -
French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC)
|